Moleculin Biotech Inc (MBRX): $4.20 by Friday

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	23
Posts	965
Boards Moderated	0
Alias Born	03/02/2012

J.T. Marlin

Re: 420man post# 2156

Tuesday, 03/17/2020 8:36:40 AM

Tuesday, March 17, 2020 8:36:40 AM

$4.20 by Friday

Keep Last Read

Replies (2) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent MBRX News

Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 12:40:16 PM
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available • PR Newswire (US) • 10/17/2024 12:40:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 12:30:19 PM
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 • PR Newswire (US) • 10/07/2024 12:30:00 PM
Moleculin to Present at Two Upcoming Investor Conferences • PR Newswire (US) • 10/04/2024 01:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2024 08:30:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 12:00:16 PM
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma • PR Newswire (US) • 09/23/2024 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:31:07 PM
Moleculin Participates in Virtual Investor "What this Means" Segment • PR Newswire (US) • 09/16/2024 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 12:15:29 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/13/2024 08:15:24 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/13/2024 08:04:30 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:15:12 PM
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma • PR Newswire (US) • 09/09/2024 12:15:00 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 09/03/2024 09:15:55 PM
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/03/2024 01:15:00 PM
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar • PR Newswire (US) • 08/26/2024 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:10:01 PM
Moleculin Announces Closing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/19/2024 08:05:00 PM
Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/19/2024 02:06:59 PM
Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/16/2024 08:54:18 PM
Moleculin Announces Pricing of up to $16.5 Million Public Offering • PR Newswire (US) • 08/16/2024 12:00:00 PM
Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/16/2024 04:15:15 AM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/15/2024 03:21:01 PM

More MBRX News

InvestorsHub NewsWire

SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM

Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM

Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM

Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM

Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM

SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover